Development of broad nanovaccines targeting diverse coronavirus receptor-binding sites

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

↗ Live URL (may be dead)

Document text

Principal Investigator: Daniel  Kulp
Organization: WISTAR INSTITUTE
Fiscal Year: 2022
Award: $1,244,471
Funding agency: National Institute of Allergy and Infectious Diseases

Project Summary
The first project of our pan-CoV proposal is titled ‘Development of broad nanovaccines targeting diverse
coronavirus receptor-binding sites’. Our team’s expertise will culminate in structurally guided coronavirus
nanoparticle vaccines to broaden CoV vaccine protection. This proposal utilizes our novel platform to
develop potent, RBS-focused nanoparticle vaccines to induce broad protection across CoV lineages,
escape mutations and potential pandemic CoVs that are of concern. The project aims are: (1) Create a
library of mutants that escape coronavirus immunity (2) Develop RBS-focused nanoparticle vaccines to induce
broadly neutralizing antibodies to conserved sites using nucleic acid delivery and (3) Develop vaccine regimens
to induce broad immunity and protection across diverse CoVs.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><Address><Adjuvant><Antibodies><Antibody Repertoire><Antibody Response><Antigenic Determinants><Antigens><Antisera><Automobile Driving><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding><Binding Determinants><Binding Sites><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><COVID-19 S protein><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 therapeutics><COVID-19 vaccination><COVID-19 vaccine><COVID-19 virus><COVID19 S protein><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 therapeutics><COVID19 vaccination><COVID19 vaccine><COVID19 virus><CoV emergence><CoV-2><CoV2><Combining Site><Coronaviridae><Coronaviridae Infections><Coronavirus><Coronavirus Infections><Cryo-electron Microscopy><Cryoelectron Microscopy><DNA><DNA Recombination><DNA Vaccines><Deoxyribonucleic Acid><Development><Devices><Disease Outbreaks><Dose><Electron Cryomicroscopy><Electroporation><Epitopes><Escape Mutant><Extensive Disease><FDA EUA><FDA Emergency Use Authorization><Food and Drug Administration EUA><Food and Drug Administration Emergency Use Authorization><Frequencies><Generalized Disease><Generations><Genetic><Genetic Alteration><Genetic Change><Genetic Recombination><Genetic defect><Genetics-Mutagenesis><HCoV><Human><Immune Sera><Immune response><Immunity><Immunization><Immunization Programs><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunostimulation><Investigation><Libraries><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Modeling><Modern Man><Molecular><Molecular Interaction><Mutagenesis><Mutagenesis Molecular Biology><Mutate><Mutation><Naked DNA Vaccines><Nucleic Acids><Outbreaks><Phenotype><Preclinical Testing><Publishing><R-Series Research Projects><R01 Mechanism><R01 Program><Reactive Site><Receptor Protein><Recombinant DNA Vaccines><Recombination><Regimen><Research Grants><Research Project Grants><Research Projects><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 therapeutics><SARS-CoV-2 vaccination><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 therapeutics><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><T8 Cells><T8 Lymphocytes><Technology><Transgenic Animals><Vaccination Programs><Vaccine Clinical Trial><Vaccines><Variant><Variation><Virus><Widespread Disease><Wuhan coronavirus><animal data><base><beta CoV><beta coronavirus><betaCoV><betacoronavirus><clinical translation><combat><corona virus><corona virus disease 2019 vaccine><corona virus emergence><coronavirus disease 2019 S protein><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 therapeutics><coronavirus disease 2019 vaccination><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus emergence><coronavirus receptor><coronavirus vaccine><cross reactivity><cryo-EM><cryoEM><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><driving><electroporative delivery><emergency use authorization><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><experiment><experimental research><experimental study><gene electrotransfer><genome mutation><hCoV19><host response><human CoV><human corona virus><human coronavirus><immune serum><immune system response><immunogen><immunogenicity><immunoresponse><interest><lead candidate><mutant><nCoV><nCoV2><nano particle><nano particle delivery><nano vaccine><nano-sized particle><nanoparticle><nanoparticle delivered><nanoparticle delivery><nanosized particle><nanovaccine><neutralizing antibody><new CoV><new corona virus><new coronavirus><novel><novel CoV><novel corona virus><novel coronavirus><nucleic acid delivery><pan CoV vaccine><pan coronavirus vaccine><panCoV vaccine><pancoronavirus vaccine><pandemic><pandemic disease><pathogenic virus><plasmid DNA><pre-clinical><pre-clinical testing><preclinical><programs><receptor><receptor binding><receptor bound><severe acute respiratory syndrome-CoV><synergism><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><universal CoV vaccine><universal coronavirus vaccine><vaccinate against COVID-19><vaccinate against COVID19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination against COVID-19><vaccination against COVID19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine against coronavirus><vaccine candidate><vaccine development><vaccine for novel coronavirus><vaccinology><viral pathogen><virus pathogen><β CoV><β coronavirus><βCoV>